Anika Therapeutics, Inc. (ANIK) Tops Q2 EPS by 3c, Revenue Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Wall St set for higher open as SpaceX, Super Micro results rekindle AI trade
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.44 --0%
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $26.3 million versus the consensus estimate of $28.2 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plumas Bancorp (PLBC) Tops Q3 EPS by 15c
- Barclays cuts Cirrus Logic price target to $95 from $130, cuts to Underweight
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
